Clinical Trials
28 trialsNCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03560908 2025-05-01
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Withdrawn
NCT05622591 2024-08-07
Pediatric AML
Elucida Oncology
Phase 1 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT05279859 2022-06-15
HERKULES-4
Erasca, Inc.
Phase 1/2 Withdrawn
NCT00900120 2021-09-21
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03121079 2020-09-23
Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
Peking University People's Hospital
Phase NA Withdrawn
NCT03207334 2018-10-22
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
Phase 2 Withdrawn
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02204020 2018-03-30
UPCI 13-165
University of Pittsburgh
Phase 2 Withdrawn
NCT02269579 2018-03-14
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT03138395 2017-08-31
iCare3
University of Florida
Withdrawn
NCT02215629 2017-01-27
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Verastem, Inc.
Phase 1 Withdrawn
NCT01520805 2016-12-29
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT02420938 2016-12-06
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00002956 2016-03-21
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT00458744 2014-08-08
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Children's Oncology Group
Phase 1 Withdrawn
NCT00898612 2014-03-10
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
Mayo Clinic
Withdrawn
NCT01649622 2012-11-08
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00402935 2012-03-20
Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer
Case Comprehensive Cancer Center
Withdrawn
NCT00378781 2012-02-24
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
M.D. Anderson Cancer Center
Phase NA Withdrawn
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn